Core Viewpoint - The company, Innovent Biologics (02121.HK), announced the repurchase of 590,700 shares in the open market for a total consideration of HKD 4.81 million, reflecting confidence in its business outlook and future prospects [1] Summary by Relevant Sections - Share Repurchase Details - The company repurchased a total of 590,700 shares at a cost of HKD 4.81 million [1] - Regulatory Compliance - The share repurchase will comply with the company's articles of association, the Hong Kong Stock Exchange listing rules, and applicable laws and regulations [1] - Management's Perspective - The board believes that the share repurchase demonstrates confidence in the company's business outlook and will ultimately benefit the company and create value for shareholders [1] - Financial Position - The board asserts that the company's existing financial resources are sufficient to support the share repurchase while maintaining a robust financial position [1]
创新奇智(02121.HK)9月合共购回59.07万股